Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Clin Cancer Res. 2019 Apr 1;25(7):2042-2048. doi: 10.1158/1078-0432.CCR-18-1625. Epub 2018 Nov 16.
Glioblastoma (GBM) is a devastating disease with an extremely poor prognosis. Immunotherapy via adoptive cell transfer (ACT), especially with T cells engineered to express chimeric antigen receptors (CAR), represents a particularly promising approach. Despite the recent success of CAR T cells for blood cancers, the question remains whether this powerful anticancer therapy will ultimately work for brain tumors, and whether the primary immunologic challenges in this disease, which include antigenic heterogeneity, immune suppression, and T-cell exhaustion, can be adequately addressed. Here, we contextualize these concepts by reviewing recent developments in ACT for GBM, with a special focus on pioneering clinical trials of CAR T-cell therapy.
胶质母细胞瘤（GBM）是一种预后极差的毁灭性疾病。通过过继细胞转移（ACT）进行免疫治疗，特别是使用工程化表达嵌合抗原受体（CAR）的 T 细胞，是一种特别有前途的方法。尽管嵌合抗原受体 T 细胞在血液癌症方面最近取得了成功，但仍存在一个问题，即这种强大的抗癌疗法最终是否适用于脑肿瘤，以及这种疾病中的主要免疫挑战，包括抗原异质性、免疫抑制和 T 细胞衰竭，是否可以得到充分解决。在这里，我们通过回顾 ACT 治疗 GBM 的最新进展，特别是 CAR T 细胞治疗的开创性临床试验，来理解这些概念。
